|Year : 2021 | Volume
| Issue : 2 | Page : 54-58
Primary cutaneous gamma-delta T-cell lymphoma: Two cases and a review of the literature
Matthew L Hrin1, Megan R Newsom1, Rima I Ghamrawi1, Angela G Niehaus2, Steven R Feldman3, Justin R Sigmon4, Lindsay C Strowd1
1 Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
2 Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
3 Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine; Department of Pathology; Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Department of Dermatology, University of Southern Denmark, Odense, Denmark
4 Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
|Date of Submission||18-Jun-2021|
|Date of Acceptance||24-Aug-2021|
|Date of Web Publication||29-Mar-2022|
Mr. Matthew L Hrin
Department of Dermatology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1071
Source of Support: None, Conflict of Interest: None
Background: Primary cutaneous gamma delta T cell lymphoma (PCGD TCL) is a rare and rapidly progressive cutaneous malignancy that can be diagnostically challenging. Purpose: To improve characterization of the clinical and histologic features of PCGD-TCL. Methods: We present two patients with PCGD TCL and review an additional 97 PCGD TCL cases from the English literature. Results: A 51 year old male with biopsy proven psoriasis and a previously healthy 31 year old male with vitiligo developed PCGD-TCL. Initial biopsy specimens in both patients suggested tumor stage mycosis fungoides (MF), but subsequent histopathology confirmed PCGD TCL. Ninety-seven patients were identified in the literature, mostly males (53%) with a mean age of 55.2 years. Lesions most commonly involved the lower (60%) and upper (30%) extremities and existed a mean of 26 months before diagnosis. The most common immunohistochemical markers were EBV(-), CD3(+), CD4(-), CD5(-), CD7(-), CD8(-), CD30(-), CD56(+), granzyme-B(+), perforin(+), and βF1(-). Radiation and CHOP chemotherapy were the most common interventions and 52% of patients died. Conclusion: PCGD TCL is a devastating disease that can clinically and histologically mimic more common dermatologic conditions, such as psoriasis and MF, and its diagnosis may require multiple biopsies and review by a multi specialty pathology team.
Keywords: Cutaneous T-cell lymphoma, hemophagocytic lymphohistiocytosis, mycosis fungoides, primary cutaneous gamma-delta T-cell lymphoma, psoriasis
|How to cite this article:|
Hrin ML, Newsom MR, Ghamrawi RI, Niehaus AG, Feldman SR, Sigmon JR, Strowd LC. Primary cutaneous gamma-delta T-cell lymphoma: Two cases and a review of the literature. J Dermatol Dermatol Surg 2021;25:54-8
|How to cite this URL:|
Hrin ML, Newsom MR, Ghamrawi RI, Niehaus AG, Feldman SR, Sigmon JR, Strowd LC. Primary cutaneous gamma-delta T-cell lymphoma: Two cases and a review of the literature. J Dermatol Dermatol Surg [serial online] 2021 [cited 2022 May 19];25:54-8. Available from: https://www.jddsjournal.org/text.asp?2021/25/2/54/341210
| Introduction|| |
Cutaneous lymphomas are a diverse group of non-Hodgkin lymphomas. Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a rare subtype, which accounts for less than one percent of all cases of cutaneous lymphoma. Its rarity precludes extensive study, and there is currently no standardized treatment protocol. In addition, PCGD-TCL is characterized by heterogeneous presentations, clinical courses, and immunophenotypes, which may present a diagnostic challenge. We present two patients with PCGD-TCL followed by a review of an additional 97 PCGD-TCL cases from the English literature.
A 51-year-old male with a several-year history of psoriasis refractory to hydrocortisone and triamcinolone presented to clinic with disease flare. A physical examination revealed psoriasiform plaques of the bilateral upper and lower extremities, bilateral hands, and trunk (15% body surface area) [Figure 1]a, [Figure 1]b, [Figure 1]c. The patient was treated with apremilast and clobetasol. Two months later, after discontinuation of apremilast, the patient's condition worsened, and additional lesions appeared on both arms. A punch biopsy specimen from the right lower flank demonstrated epidermal hyperplasia with suprapapillary thinning, focal diminution of the granular layer, parakeratosis, Munro's microabscesses, and focal spongiosis, findings consistent with psoriasis [Figure 2]a and [Figure 2]b. A complete blood count and a complete metabolic panel were unremarkable. An infectious workup was negative for tuberculosis and viral hepatitis.
|Figure 1: Patient one: Psoriasiform plaques on (a) left arm, (b) right hand, and (c) left trunk|
Click here to view
|Figure 2: Patient one: (a) H and E, ×4, (b) H and E, ×20: Epidermal hyperplasia with suprapapillary thinning, focal diminution of the granular layer, parakeratosis, Munro's microabscesses, and focal spongiosis|
Click here to view
Despite starting oral methotrexate (10 mg weekly) three months after the initial visit, the patient's lesions continued to enlarge and became bullae, spreading to the neck, face, and scalp, raising concern for pustular psoriasis. The lesions worsened over the next month despite additional treatment with 100 mg/mL guselkumab, and the patient developed tumor-like nodules [Figure 3]a and [Figure 3]b. A review of systems was negative for fevers, night sweats, cough, and recent foreign travel. A computed tomography (CT) scan of the chest, abdomen, and pelvis revealed mildly enlarged axillary, common femoral, and inguinal lymph nodes. A repeat punch biopsy of the left lower back demonstrated an atypical epidermal atrophic and dermal lymphoid infiltrate, characteristic of mycosis fungoides (MF) [Figure 4]a and [Figure 4]b. Given the patient's atypical clinical presentation and rapid progression from plaques to tumors, additional dermatopathologic evaluation was pursued. The infiltrate immunophenotype was: T-cell receptor (TCR)-δ(+)/CD2(−)/CD3(+)/CD4(−)/CD5(−)/CD8(−)/CD30(−)/CD56(−)/BF1(−)/TIA-1(+)/CD45RA(+). Epstein–Barr encoding region-1 in situ hybridization was negative and Ki67 (MIB-1) monoclonal antibody markers showed proliferative activity of approximately 80%, characteristic of a high-grade tumor. A diagnosis of PCGD-TCL with cytotoxic activity was confirmed. The patient was started on EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin); after four months of chemotherapy, the patient began adjuvant radiation therapy with the goal of remission and eventual stem cell transplant. However, the patient died slightly over 2 years from the time of diagnosis.
|Figure 3: Patient one: Psoriasiform plaques with tumor-like nodules on the (a) right hand and (b) left trunk|
Click here to view
|Figure 4: Patient one: (a) H and E, ×2, (b) H and E, ×10: Dense dermal infiltrate composed of large pleomorphic lymphocytes with scattered mononuclear cells, eosinophils, histiocytes, and plasma cells. The epidermis shows extensive epidermotropism with acanthosis, spongiosis, and necrotic keratinocytes|
Click here to view
A 31-year-old Caucasian male with a diagnosis of vitiligo presented to his primary care physician with a firm, painful 3 cm × 2 cm lesion over his right thigh. Despite several courses of antibiotics, the lesion enlarged and additional smaller nodules appeared in his right groin. A skin biopsy was suspicious for cutaneous T-cell lymphoma.
Four months later, the patient presented to our institution with a large erythematous plaque accompanied by several punctate ulcerations over the right lateral thigh and smaller plaques on the left thigh and right calf [Figure 5]a and [Figure 5]b. He endorsed intermittent fever but denied night sweats, chills, and weight loss. Physical examination was negative for palpable lymphadenopathy. His serum transaminase and lactate dehydrogenase levels were elevated. A biopsy specimen showed a dense infiltrate of atypical lymphocytes in the dermis extending to the subcutaneous fat [Figure 6]a and [Figure 6]b. Immunohistochemistry identified atypical T-cells with an elevated CD4:CD8 ratio, CD5(−), and granzyme-B(−), suggestive of tumor-stage MF. Subsequent bone marrow biopsy showed no evidence of T-cell disease. A CT scan revealed inguinal lymphadenopathy and hepatomegaly. He was started on 75 mg daily bexarotene with a plan to increase to 600 mg daily.
|Figure 5: Patient two: Large plaque with ulcerations over (a) right posterior-lateral thigh, and (b) progression with bilateral lower extremity involvement|
Click here to view
|Figure 6: Patient two: (a) H and E, ×2, (b) H and E, ×10: diffuse lymphocytic infiltrate involving the superficial vessels, the mid peri-adnexal structures, and the underlying subcutaneous tissue with rimming of fat cells|
Click here to view
Immunohistochemical stains of a repeat biopsy seven weeks later identified CD3(+), granzyme-B(+), CD7(−) T-cells, characteristic of a cytotoxic T-cell phenotype [Figure 7]a and [Figure 7]b. The tumor cells were βF1(−), CD56(+) [Figure 7]c. Polymerase chain reaction assay showed gamma rearrangement of the TCR and immunohistochemistry for gamma-delta showed diffuse, strong staining in the atypical lymphocytic infiltrate [Figure 7]d. The patient was diagnosed with PCGD-TCL and was started on daily dose-adjusted EPOCH chemotherapy with the goal of allogenic bone marrow transplant once disease control was achieved.
|Figure 7: Patient two: immunohistochemistry staining of tumor cell infiltrate, H and E, ×4: (a) CD3(+), (b) CD7(-), (c) CD56(+), and (d) gamma-delta|
Click here to view
Despite two cycles of EPOCH and one cycle of ifosfamide, carboplatin, and etoposide chemotherapy, the patient's disease continued to progress. He had a partial response after two cycles of CPI-613 with bendamustine, but this was discontinued after he experienced two grand-mal seizures. Six months after his diagnosis, a bone marrow biopsy revealed hemophagocytic lymphohistiocytosis (HLH), with a serum ferritin level greater than 25,000. The patient failed to improve with etoposide, dexamethasone, and alemtuzumab, and a bone marrow transplant became nonviable. He passed away seven months after initial diagnosis.
| Methods|| |
A systematic review of the literature was performed in the MEDLINE (PubMed) database using the keywords, “primary cutaneous gamma-delta T-cell lymphoma.” This search identified 68 publications, 63 of which were accessible and encompassed a total of 97 cases of PCGD-TCL. We reviewed demographic data, presenting features, treatment regimens, and clinical responses.
| Results|| |
Ninety-seven patients, mostly males (52.6%) with a mean age of 55.2 ± 18.4 years (median 57 years; range 1.5–88 years), were identified in the literature. Their presentation characteristics, treatment regimens, and outcomes are summarized in [Table 1] and [Table 2].
|Table 1: Presentation characteristics of 97 primary cutaneous gamma-delta T-cell lymphoma patients|
Click here to view
|Table 2: Treatment regimens and outcomes of 97 primary cutaneous gamma-delta T-cell lymphoma patients|
Click here to view
| Discussion|| |
PCGD-TCL is a rare and aggressive T-cell lymphoma caused by clonal expansion of mature cytotoxic gamma-delta T-cells, a peripheral T-cell seen in epithelial and mucosal tissues., Gamma-delta T-cells are divided into two subpopulations, Vδ1 and Vδ2, based on the variable region of the delta chain of their TCR. While both functional subsets may give rise to PCGD-TCL, each subtype has its own clinically relevant distinguishing features. Differences in Vδ1 and Vδ2 tropism for skin layers and differential production of cytotoxic cytokines partially explain PCGD-TCL's heterogeneity, and epidermal-derived lesions carry a better prognosis than dermal or subcutaneously-derived infiltrates.,,
PCGD-TCL is more common among middle-aged individuals and may be more likely to affect men than subcutaneous panniculitis-like T-cell lymphoma., However, there are reports of the disease occurring in children with variable outcomes.,,, It most commonly presents as plaques and ulcerating lesions over the extremities, as seen in our two cases, but may also present as panniculitis, erythroderma, pyoderma, cellulitis, and rarely, Sezary syndrome.,,,,,, Extracutaneous manifestations, such as bone metastasis and central nervous system involvement, have also been described., Unlike other lymphomas, the spleen, bone marrow, and lymph nodes are rarely involved. If splenic involvement is evident, PCGD-TCL can be confused with a similar, but distinct lymphoma: hepatosplenic gamma-delta lymphoma. Another variant of cutaneous malignancy involving a gamma-delta lineage that can present with ulcerating plaques is extranodal T-cell lymphoma, which may be differentiated from PCGD-TCL by its classical expression of CD8(+) and EBV(+). While PCGD-TCL can present a diagnostic challenge, laboratory tests, such as lactate dehydrogenase levels, may help support a diagnosis of lymphoma.
The clinical course of PCGD-TCL is typically very aggressive with a five-year survival rate of approximately 10%. The development of HLH in the setting of PCGD-TCL indicates a poor prognosis, as seen in our second case presentation and reflected in our literature review.,,,,,,,, Cases of indolent disease progression have occurred, but one patient suffered rapid deterioration and death after a 15-year indolent course; atypical expression of markers, such as βF1(+), CD30(+), and CD4(+), may be indicators of less aggressive disease.,,,,,
While comorbid inflammatory disease has not been consistently described, chronic antigen stimulation and immunosuppression may contribute to its pathogenesis. Several patients have developed PCGD-TCL in the setting of systemic inflammatory disease including Behcet's syndrome, rheumatoid arthritis, psoriasis, and ankylosing spondylitis.,,, There are at least two patients whose disease became clinically apparent after beginning biologic therapy, including one of our case presentations and a patient with rheumatoid arthritis. It is unclear if longstanding T-cell inflammation or immunomodulation contributed to disease onset in these cases.
According to the World Health Organization and the European Organization for Research and Treatment of Cancer, the cells of PCGD-TCL are classically CD3(+), CD4(−), CD8(+/-), CD56(+), and EBV(−). However, many immunophenotypical variants have been reported. Several cases, including both of our patients, were initially diagnosed with MF based on the first biopsy specimen.,,,, Other histopathologic features, such as Pautrier microabscesses, may further mislead pathologists.
The treatment of PCGD-TCL usually involves lymphotoxic chemotherapy, sometimes with concomitant cutaneous radiation. Depending on the immunophenotype, targeted immunotherapies may present an additional treatment option; for example, brentuximab vedotin, an anti-CD30 antibody, can be used for CD30(+) disease. However, hematopoietic stem cell transplant appears to be the only curative treatment option and may be associated with safety risks. At least one patient developed multiple complications after allogenic stem cell transplant: BK virus-associated cystitis, ocular herpes simplex, and bronchiolitis obliterans – before dying from graft-versus-host-disease. Another patient developed PCGD-TCL shortly after receiving an allogenic stem cell transplant for MF.
| Conclusion|| |
PCGD-TCL is a rare disease plagued by a limited knowledge fund. Diagnosis can be difficult due to its variable clinical presentation and the histologic similarities it shares with more common cutaneous pathologies. The two cases presented, along with our literature review, serve as a reminder that repeat biopsies may be indicated for cases of dermatoses that exhibit unusual behavior.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the legal guardian has given his consent for images and other clinical information to be reported in the journal. The guardian understands that names and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al.
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14.
Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, et al
. Cutaneous γδ T-cell lymphomas: A spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 2012;36:1656-65.
Daniels J, Doukas PG, Escala ME, Ringbloom KG, Shih DJ, Yang J, et al.
Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat Commun 2020;11:1806.
Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, et al.
Primary cutaneous T-cell lymphomas showing gamma-delta (γδ) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous γδ T-cell lymphomas. Am J Surg Pathol 2017;41:204-15.
Goyal A, Goyal K, Bohjanen K, Pearson D. Epidemiology of primary cutaneous γδ T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the U.S.A. from 2006 to 2015: A surveillance, epidemiology, and end results-18 analysis. Br J Dermatol 2019;181:848-50.
Vin H, Talpur R, Tetzlaff MT, Duvic M. T-cell receptor-γ in gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCRβF1 and an indolent clinical course. Clin Lymphoma Myeloma Leuk 2014;14:e195-200.
Soon CW, Link M, Kim YH, Kim J. Primary cutaneous gamma-delta T-cell lymphoproliferative disorder in a 3-year-old boy. Am J Dermatopathol 2015;37:567-9.
Garcia-Herrera A, Song JY, Chuang SS, Villamor N, Colomo L, Pittaluga S, et al
. Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol 2011;35:1214-25.
Kerbout M, Mekouar F, Bahadi N, El Omri N, Assoufi N, El Qatni M, et al
. A rare pediatric case of cutaneous gamma/delta T-cell lymphoma. Ann Biol Clin (Paris) 2014;72:483-5.
Murphy WS, Yeh JE, Nazarian RM, Sohani AR, Kvedar J, Kroshinsky D. A case of fever and erythema nodosum-like lesions leading to a new diagnosis of gamma-delta T-Cell lymphoma complicated by hemophagocytic lymphohistiocytosis. Dermatopathology (Basel) 2019;6:266-70.
Benecke J, Géraud C, Nicolay JP. Cutaneous gamma-delta T-cell lymphoma with an initially indolent course mimicking lupus panniculitis. Acta Derm Venereol 2017;97:665-6.
Patsatsi A, Koletsa T, Sotiriadis D, Batsis I, Sakellari I, Anagnostopoulos A, et al.
Silent T-cell lymphoma of γδ T-cell origin initially presented as panniculitis. J Eur Acad Dermatol Venereol 2015;29:1244-5.
Yi L, Qun S, Wenjie Z, Wen Z, Jian L, Yan Z, et al.
The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γδ T-cell lymphoma may mimic those of rheumatic diseases: A report of 11 cases. Clin Rheumatol 2013;32:1169-75.
Aguilera P, Mascaró JM Jr., Martinez A, Esteve J, Puig S, Campo E, et al.
Cutaneous gamma/delta T-cell lymphoma: A histopathologic mimicker of lupus erythematosus profundus (lupus panniculitis). J Am Acad Dermatol 2007;56:643-7.
Bauer W, Spazierer D, Klein I, Stary G, Wöhrl S, Wagner SN, et al.
γδ T-cell lymphoma mimicking Sézary syndrome. Acta Derm Venereol 2012;92:166-8.
Jagati A, Shah BJ, Tibrewal S, Gajjar T. CD3+, CD56+, CD4-, CD8-, CD20-, CD30- peripheral T-cell non-hodgkin's lymphoma: A rare case report. Indian J Dermatol 2017;62:200-2.
] [Full text]
Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: Report of a rarity with review of literature. J Cutan Pathol 2014;41:936-43.
Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. Eur J Haematol 2015;94:206-18.
Ali L, Young MR, Bayerl MG, Helm KF, Clarke LE. Gamma-delta T-cell lymphoma arising in a long-standing cutaneous plaque. J Cutan Pathol 2015;42:987-91.
Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM. A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis. Clin Case Rep 2015;3:34-8.
Geller S, Myskowski PL, Pulitzer M, Horwitz SM, Moskowitz AJ. Cutaneous T-cell lymphoma (CTCL), rare subtypes: Five case presentations and review of the literature. Chin Clin Oncol 2019;8:5.
Alexander RE, Webb AR, Abuel-Haija M, Czader M. Rapid progression of primary cutaneous gamma-delta T-cell lymphoma with an initial indolent clinical presentation. Am J Dermatopathol 2014;36:839-42.
Magro CM, Wang X. Indolent primary cutaneous γ/δ T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol 2012;138:50-6.
Chakrapani A, Avery A, Warnke R. Primary cutaneous gamma delta T-cell lymphoma with brain involvement and hemophagocytic syndrome. Am J Dermatopathol 2013;35:270-2.
Caudron A, Bouaziz JD, Battistella M, Sibon D, Lok C, Leclech C, et al.
Two atypical cases of cutaneous gamma/delta T-cell lymphomas. Dermatology 2011;222:297-303.
Avinoach I, Halevy S, Argov S, Sacks M. Gamma/delta T-cell lymphoma involving the subcutaneous tissue and associated with a hemophagocytic syndrome. Am J Dermatopathol 1994;16:426-33.
Endly DC, Weenig RH, Peters MS, Viswanatha DS, Comfere NI. Indolent course of cutaneous gamma-delta T-cell lymphoma. J Cutan Pathol 2013;40:896-902.
Hosler GA, Liégeois N, Anhalt GJ, Moresi JM. Transformation of cutaneous gamma/delta T-cell lymphoma following 15 years of indolent behavior. J Cutan Pathol 2008;35:1063-7.
Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol 2009;89:653-4.
Chelly I, Limaïem F, Mekni A, Bellil S, Bellil K, Ghorbel IB, et al.
Cutaneous gamma-delta T-cell lymphoma arising in the setting of Behcet's disease. Pathologica 2008;100:166-9.
Suga H, Sugaya M, Miyagaki T, Ohmatsu H, Fujita H, Sato S. Primary cutaneous γδ T-cell lymphoma following mycosis fungoides. Int J Dermatol 2014;53:e82-4.
Fujii M, Uehara J, Honma M, Ito Y, Takahashi H, Ishida-Yamamoto A, et al.
Primary cutaneous γδ-T-cell lymphoma treated with low-dose methotrexate and narrowband ultraviolet B irradiation: Report of a case with testicular involvement. J Dermatol 2011;38:368-72.
Munn SE, McGregor JM, Jones A, Amlot P, Rustin MH, Russell Jones R, et al.
Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: A report of three cases and a review of the literature. Br J Dermatol 1996;135:976-81.
Rubio-Gonzalez B, Zain J, Garcia L, Rosen ST, Querfeld C. Cutaneous gamma-delta T-Cell lymphoma successfully treated with brentuximab vedotin. JAMA Dermatol 2016;152:1388-90.
Kato K, Namiki T, Ueno M, Iikawa M, Tokoro S, Nishizawa A, et al
. A case of primary cutaneous gamma-delta T-cell lymphoma with pautrier microabscess. Ann Dermatol 2017;29:229-32.
Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, et al.
Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. J Am Acad Dermatol 2015;72:1010-5.e5.
Terras S, Moritz RK, Ditschkowski M, Beelen DW, Altmeyer P, Stücker M, et al.
Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous γ/δ-T-cell lymphoma. Acta Derm Venereol 2013;93:360-1.
Bautista-Quach MA, Tong T, Nademanee A, Huang Q. Primary cutaneous gamma-delta T-cell lymphoma with marked pagetoid epidermotropism shortly after allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2013;13:e6-9.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
[Table 1], [Table 2]